Global Long Read Sequencing Market is expected to grow with the CAGR of 23.7% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-long-read-sequencing-market

Global long read sequencing market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in global long read sequencing market are introducing strong range of products provider along with receiving large number of FDA & CE mark approvals for launching new products into the market. For instance, in March 2019, Oxford Nanopore introduced Flongle for rapid, short DNA / RNA sequence analysis. Flongle is an adapter which can be used with the desktop GridION X5 and portable MinION sequencing devices. Small Flongle cells that can produce as much as 1.8 Gb of sequence data with headroom for more than 3 Gb. This product launch will help in the strengthening of the company’s product portfolio.

Illumina, Inc., is the dominating player in global long read sequencing market. The other key players existing in the market includes Oxford Nanopore Technologies, PerkinElmerInc., Thermo Fisher Scientific, Inc., Novogene Corporation, Macrogen, Inc., BaseClear B.V., GENEWIZ Inc. (A subsidiary of Brooks Automation, Inc.), Pacific Biosciences of California, Inc., Takara Bio Inc., TATAA Biocenter, FG Technologies, Roche Sequencing (A subsidiary of F. Hoffmann-La Roche Ltd), Universal Sequencing Technology (UST), QIAGEN, BioCat GmbH, LOOP GENOMICS, BGI, Lexogen GmbH, Promega Corporation, Agilent Technologies, Inc, Longas Technologies and Quantapore, Inc. and among others.

Illumina, Inc. :

Illumina, Inc., headquartered in California, U.S. was founded in 1998. The company is engaged in manufacturing, developing and trading of the integrated systems and life science tools which offer the large scale analysis of genetic variation and function. The company has business segment named as core illumina. The company also has wide product portfolio including instruments, kits & reagents, selection tools, software & analysis, services and popular products among which instruments and kits & reagents are the market focused category. 

For instance,

• In November 2018, Illumina, Inc. and Pacific Biosciences have signed an agreement for Illumina to acquire Pacific Biosciences at a price of USD 8.00 per Pacific Biosciences share. The approval for this agreement is given by the board of directors of Illumina and Pacific Biosciences. This acquisition offers Illumina sequencing solutions with accurate long-read sequencing capabilities for set of complex genomic questions. Therefore it provides access to long-read sequencing and accelerating scientific discovery. The development makes the company’s product portfolio advanced in the market.

The company also has wide global presence across Asia-Pacific, Europe, Middle East and Africa, and Americas. The various subsidiaries of Illumina, Inc. includes BlueGnome, Ltd. (UK), Conexio Genomics Pty Ltd. (Australia), Illumina Cambridge, Ltd. (UK), Illumina Canada, Inc (Canada), Illumina Scientific Co Ltd (China) among more.

Thermo Fisher Scientific Inc :

Thermo Fisher Scientific Inc., headquartered in Massachusetts, U.S. was founded in 1902. The company is engaged in serving science in order to make the world healthier, cleaner and safer by offering applications & techniques in life sciences, industrial & applied science, clinical & diagnostics, lab solutions and other resources out of which the market focused category is life sciences. The business segments include laboratory products and services, life sciences solutions, analytical instruments, specialty & diagnostics among which life sciences solutions is the market focused segment.

For instance,

•  In March 2020, Thermo Fisher Scientific Inc. announced the acquisition of the QIAGEN N.V. Thermo Fischer got the approval of acquiring the QIAGEN for Euro 39 per share in cash. This acquisition helps in improving the product portfolio and increasing the revenues of the company as well as the global reach in the market.

The company has wide presence across Americas, Europe, Middle East and Africa, Eastern Europe, and Asia. The company also generates revenue from its subsidiaries wich includes Thermo Fisher Scientific Operating Company LLC (Delaware), Thermo Fisher Scientific Senior Financing LLC (Delaware), Thermo Fisher Scientific Africa Proprietary Ltd ( south Africa), NovaWave Technologies, Inc. (California), Thermo Fisher Germany B.V. (Netherland) and among others.

Oxford Nanopore Technologies :

Oxford Nanopore Technologies, headquartered in Oxford, U.K. was founded in 2005. The company offers rapid, portable and easy to use real time nanopore based sequencing instruments. It focuses on various areas such as human genomics, cancer research, microbiology, plant science and environmental research. The company offers wide product portfolio categories including SmidgION, Flongle, MinION, GridION, promethION and Plonglein.  

For instance,

• In February 2020, Oxford Nanopore Technologies signed a licensing agreement with NuProbe. Under this agreement, Oxford Nanopore will combine its Nanopore sequencing with NuProbe’s Blocker Displacement Amplification technology for greater detection sensitivities and quantify somatic mutations at less than 5% allele frequency. This agreement will help Oxford Nanopore to expand its product application.

The company has wide presence across North America, Europe and Asia-Pacific.